Date: 2017-04-18
Type of information: Nomination
Compound: chief scientific officer
Company: Ipsen (France)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On April 14, 2017, Ipsen announced the appointment of Dr. Alexandre Lebeaut as Executive Vice-President, R&D, and Chief Scientific Officer, effective immediately. Dr. Lebeaut will report directly to David Meek, CEO of Ipsen, and serve on the Executive Leadership Team.
- Dr. Lebeaut joined Ipsen in 2013 as Senior Vice President, Chief Development Officer, Global Drug Development and was appointed Interim Head of R&D in December 2016.
Dr. Lebeaut earned his M.D. from Paris Diderot University and specialized in Pediatrics from Paris Descartes University. Before joining Ipsen, he held several global leadership positions in Clinical Development and Medical Affairs with biopharmaceutical companies including Axcan Pharmaceuticals, Sanofi, Novartis and Schering Plough Research Institute.
Financial terms:
Latest news:
Is general: Yes
